These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22683343)

  • 1. Design, synthesis and structure-activity relationships of 5-alkylaminolquinolines as a novel series of CRF1 receptor antagonists.
    Takeda K; Terauchi T; Shin K; Ino M; Shibata H; Yonaga M
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4756-61. PubMed ID: 22683343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and structure-activity relationships of a series of 2-Ar-8-methyl-5-alkylaminoquinolines as novel CRF₁ receptor antagonists.
    Takeda K; Terauchi T; Hashizume M; Shin K; Ino M; Shibata H; Yonaga M
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5372-8. PubMed ID: 22871582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
    Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design, synthesis and structure-activity relationships of 1-aryl-4-aminoalkylisoquinolines: a novel series of CRF-1 receptor antagonists.
    Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Chandrasekhar J; Horvath RF; Ge P; Kershaw MT; Krause JE; Kehne J; Hoffman D; Doller D; Hodgetts KJ
    Bioorg Med Chem Lett; 2008 Feb; 18(3):891-6. PubMed ID: 18180159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and SAR of 8-arylquinolines as potent corticotropin-releasing factor1 (CRF1) receptor antagonists.
    Huang CQ; Wilcoxen K; McCarthy JR; Haddach M; Webb TR; Gu J; Xie YF; Grigoriadis DE; Chen C
    Bioorg Med Chem Lett; 2003 Oct; 13(19):3375-9. PubMed ID: 12951129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design.
    Ye Y; Liao Q; Wei J; Gao Q
    Neurochem Int; 2010 Jan; 56(1):107-17. PubMed ID: 19782115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists.
    Hartz RA; Nanda KK; Ingalls CL; Ahuja VT; Molski TF; Zhang G; Wong H; Peng Y; Kelley M; Lodge NJ; Zaczek R; Gilligan PJ; Trainor GL
    J Med Chem; 2004 Sep; 47(19):4741-54. PubMed ID: 15341489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists.
    Takahashi Y; Hashizume M; Shin K; Terauchi T; Takeda K; Hibi S; Murata-Tai K; Fujisawa M; Shikata K; Taguchi R; Ino M; Shibata H; Yonaga M
    J Med Chem; 2012 Oct; 55(19):8450-63. PubMed ID: 22971011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design, synthesis, and structure-activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonists.
    Lowe RF; Nelson J; Dang TN; Crowe PD; Pahuja A; McCarthy JR; Grigoriadis DE; Conlon P; Saunders J; Chen C; Szabo T; Chen TK; Bozigian H
    J Med Chem; 2005 Mar; 48(5):1540-9. PubMed ID: 15743196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
    Hartz RA; Ahuja VT; Schmitz WD; Molski TF; Mattson GK; Lodge NJ; Bronson JJ; Macor JE
    Bioorg Med Chem Lett; 2010 Mar; 20(6):1890-4. PubMed ID: 20176478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Arylpyrimidines: novel CRF-1 receptor antagonists.
    Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Krause JE; Hutchison A; Horvath RF; Ge P; Kehne J; Hoffman D; Chandrasekhar J; Doller D; Hodgetts KJ
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4486-90. PubMed ID: 18672365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.
    Hartz RA; Ahuja VT; Arvanitis AG; Rafalski M; Yue EW; Denhart DJ; Schmitz WD; Ditta JL; Deskus JA; Brenner AB; Hobbs FW; Payne J; Lelas S; Li YW; Molski TF; Mattson GK; Peng Y; Wong H; Grace JE; Lentz KA; Qian-Cutrone J; Zhuo X; Shu YZ; Lodge NJ; Zaczek R; Combs AP; Olson RE; Bronson JJ; Mattson RJ; Macor JE
    J Med Chem; 2009 Jul; 52(14):4173-91. PubMed ID: 19552437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists.
    Huang CQ; Grigoriadis DE; Liu Z; McCarthy JR; Ramphal J; Webb T; Whitten JP; Xie MY; Chen C
    Bioorg Med Chem Lett; 2004 May; 14(9):2083-6. PubMed ID: 15080983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationships of 8-substituted-2-aryl-5-alkylaminoquinolines: Potent, orally active corticotropin-releasing factor-1 receptor antagonists.
    Takeda K; Terauchi T; Hashizume M; Shikata K; Taguchi R; Murata-Tai K; Fujisawa M; Takahashi Y; Shin K; Ino M; Shibata H; Yonaga M
    Bioorg Med Chem; 2012 Nov; 20(22):6559-78. PubMed ID: 23062820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists.
    Saito T; Obitsu T; Kondo T; Matsui T; Nagao Y; Kusumi K; Matsumura N; Ueno S; Kishi A; Katsumata S; Kagamiishi Y; Nakai H; Toda M
    Bioorg Med Chem; 2011 Sep; 19(18):5432-45. PubMed ID: 21865047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-phenylphenylglycines as novel corticotropin releasing factor receptor antagonists.
    Molteni V; Penzotti J; Wilson DM; Termin AP; Mao L; Crane CM; Hassman F; Wang T; Wong H; Miller KJ; Grossman S; Grootenhuis PD
    J Med Chem; 2004 May; 47(10):2426-9. PubMed ID: 15115386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of benzoylpyrimidines as antagonists of the corticotropin-releasing factor-1 receptor.
    Webb TR; Moran T; Huang CQ; McCarthy JR; Grigoriadis DE; Chen C
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3869-73. PubMed ID: 15225687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands.
    Hartz RA; Arvanitis AG; Arnold C; Rescinito JP; Hung KL; Zhang G; Wong H; Langley DR; Gilligan PJ; Trainor GL
    Bioorg Med Chem Lett; 2006 Feb; 16(4):934-7. PubMed ID: 16297619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
    Saito T; Obitsu T; Minamoto C; Sugiura T; Matsumura N; Ueno S; Kishi A; Katsumata S; Nakai H; Toda M
    Bioorg Med Chem; 2011 Oct; 19(20):5955-66. PubMed ID: 21930387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.